Given our results of hyperactivated mTOR signaling in TTLshort leukemia, mTOR and PI3K signaling activities were addressed in response to pathway inhibition using the prototypic allosteric mTOR inhibitor rapamaycin and the dual mTOR/PI3K inhibitor NVP-BEZ235. The gene discussed is MTOR; the disease is leukemia.